Literature DB >> 12732365

Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians.

Christoph Köhle1, Bernd Möhrle, Peter A Münzel, Matthias Schwab, Dorothee Wernet, Osama A Badary, Karl Walter Bock.   

Abstract

Polymorphisms of drug metabolizing enzymes are frequently associated with diseases and side effects of drugs. Recently, a TATA box mutation of UGT1A1 (UGT1A1*28), a common genotype leading to Gilbert's syndrome, and several missense mutations of other UDP-glucuronosyltransferase 1 (UGT1) family members have been described. Furthermore, co-occurrence of UGT1A1*28 and UGT1A6*2 has been observed. In order to elucidate the basis for co-occurrence of UGT1 mutations, fluorescence resonance energy transfer techniques were developed for rapid determination of polymorphisms of three UGT isoforms (UGT1A1*28, 1A6*2, and 1A7*2/*3). Hundred healthy Caucasians and 50 Egyptians were genotyped. All genotypes followed the Hardy-Weinberg equilibrium. Only three major haplotypes were found, including a haplotype consisting of allelic variants of all three isoforms (29% in Caucasians and 22% in Egyptians), all leading to reduced UGT activity. Frequent haplotypes containing several UGT1 allelic variants should be taken into account in studies on the association between diseases, abnormal drug reactions, and UGT1 family polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732365     DOI: 10.1016/s0006-2952(03)00074-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  22 in total

1.  Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Dhandapani Kayathiri; Subramanian Rajan; Deepak Gopal Shewade; Steven Aibor Dkhar; Sajjanavar Manjunath; Prayaga Ushakiran; Gangadharan Reneega; Kukreti Ritushree; Chandrasekaran Adithan
Journal:  Mol Biol Rep       Date:  2012-02-09       Impact factor: 2.316

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Frank Z Stanczyk; Kim C Westerlind; Katherine M Newton; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-28       Impact factor: 4.292

4.  The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients.

Authors:  Suad AlFadhli; Hassan Al-Jafer; Mays Hadi; Mashael Al-Mutairi; Rasheeba Nizam
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

Review 5.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

6.  Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.

Authors:  Xiao-Man Chu; Li-Fang Zhang; Guang-Ji Wang; Shen-Ning Zhang; Jia-Hui Zhou; Hai-Ping Hao
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

7.  Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

Authors:  Shouji Shimoyama
Journal:  World J Gastrointest Surg       Date:  2010-01-27

8.  Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Authors:  Eric Lévesque; Anne-Sophie Bélanger; Mario Harvey; Félix Couture; Derek Jonker; Federico Innocenti; Erica Cecchin; Giuseppe Toffoli; Chantal Guillemette
Journal:  J Pharmacol Exp Ther       Date:  2013-02-05       Impact factor: 4.030

9.  UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).

Authors:  Paula R Pacheco; Maria J Brilhante; Cristina Ballart; Francesc Sigalat; Helena Polena; Rita Cabral; Claudia C Branco; Luisa Mota-Vieira
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  Role of atazanavir in the treatment of HIV infection.

Authors:  Pablo Rivas; Judit Morello; Carolina Garrido; Sonia Rodríguez-Nóvoa; Vincent Soriano
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.